Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono: New Products Grow in 1st Half, Glactiv to Become Top-Selling Product
November 8, 2012
- Alfresa HD “Reached Some Degree of Agreement with Customers” Despite Non-Agreement Rate of Over 60% in 1st Half: President Ishiguro
November 8, 2012
- Kyorin Drops Development of DPP-4 Inhibitor as It Fails to Find Partner
November 8, 2012
- Otsuka Forms JV with Turkey’s No. 1 Drug Maker, Set to Launch Samsca in 2013
November 7, 2012
- Tolvaptan Suppresses Rate of Increase in Total Kidney Volume by 50%: Otsuka
November 7, 2012
- Eli Lilly Japan, Chugai to Terminate Comarketing Agreement for Evista
November 7, 2012
- Takeda to Buy Envoy of US to Reinforce Drug Discovery Prowess
November 7, 2012
- Ono Achieves Target Reduction of Sales Ratio of Long-Listed Drugs to Mid-50% Level: President Sagara
November 7, 2012
- Generic Sales Ratio Exceeds 80% for First Time in Interim Results: Nippon Chemiphar
November 6, 2012
- Abbott Splits into Two Companies; Research-Based Pharmaceuticals, Diversified Medical Products
November 6, 2012
- Abbott Japan Spins Off New Drug Biz, Establishes New Firm “AbbVie”
November 6, 2012
- Sawai’s Status Improved Within Mediceo by Utilizing ARs
November 6, 2012
- Asahi Kasei Pharma 1st Half Sales Show Significant Growth, Teribone May Exceed Peak Sales in 1st Year
November 6, 2012
- Astellas Logs Sales of 25.5 Bil. Yen in Oncology Sector, Investments Bearing Fruit: Pres. Hatanaka
November 5, 2012
- Shionogi Enjoys Sales, Profit Growth in 1st Half, 8 Strategic Products Make Up 50% of Japan Sales
November 5, 2012
- Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
- Eisai to Go on Offensive for Aricept by Introducing Consultation Date Reminder Service for Patients: President Naito
November 5, 2012
- Astellas Discontinues Development of SGLT-2 Inhibitor Ipragliflozin in Europe, US; Development in Japan to Go Forward
November 5, 2012
- Astellas: Slight Sales Decline in 1st Half due to Strong Yen, Domestic Sales Virtually Unchanged
November 5, 2012
- “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…